Continuous Use of Thienopyridine May Be as Safe as Low-Dose Aspirin in Endoscopic Resection of Gastric Tum
1
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Background/Aims: Current guidelines recommend withholding antiplatelets for 5–7 days before high-risk endoscopic procedures. We investigated whether this reduces post-endoscopic submucosal dissection (ESD) bleeding. Methods: Gastric ESD cases with antiplatelets were retorospectively reviewed. Withholding antiplatelets for 5–7 days before ESD was defined as cessation and 0–4 days as continuation. The rate and risk of post-ESD bleeding according to the types and cessation of antiplatelets were assessed. Results: Among the 215 patients (117 adenoma and 98 early gastric cancer), 161 patients were on single (94 aspirin, 56 thienopyridine, and 11 other agents), 51 on dual, and 3 on triple antiplatelets. Post-ESD bleeding rates were 12.8% in aspirin users, 3.6% in thienopyridine, 27.5% in dual, 33.3% in triple therapy, and 9.7% in the cessation and 15.0% in the continuation group. Multiple antiplatelets (odds ratio [OR], 2.41; 95% confidence interval [CI], 1.01 to 5.76) and specimen size ≥ 5.5 cm (OR, 2.84; 95% CI, 1.04 to 7.73) were the risk of bleeding, while continuation of thienopyridine (OR, 0.23; 95% CI, 0.05 to 1.09) and antiplatelets (OR, 1.83; 95% CI, 0.68 to 4.94) did not increase the risk of bleeding. Conclusions: Continuing thienopyridine and aspirin did not increase the risk of post-ESD. Multiple antiplatelet therapy and a large specimen size were independent risk factors of post-ESD bleeding.
Abstract
Background/Aims: Current guidelines recommend withholding antiplatelets for 5–7 days before high-risk endoscopic procedures. We investigated whether this reduces post-endoscopic submucosal dissection (ESD) bleeding. Methods: Gastric ESD cases with antiplatelets were retorospectively reviewed. Withholding antiplatelets for 5–7 days before ESD was defined as cessation and 0–4 days as continuation. The rate and risk of post-ESD bleeding according to the types and cessation of antiplatelets were assessed. Results: Among the 215 patients (117 adenoma and 98 early gastric cancer), 161 patients were on single (94 aspirin, 56 thienopyridine, and 11 other agents), 51 on dual, and 3 on triple antiplatelets. Post-ESD bleeding rates were 12.8% in aspirin users, 3.6% in thienopyridine, 27.5% in dual, 33.3% in triple therapy, and 9.7% in the cessation and 15.0% in the continuation group. Multiple antiplatelets (odds ratio [OR], 2.41; 95% confidence interval [CI], 1.01 to 5.76) and specimen size ≥ 5.5 cm (OR, 2.84; 95% CI, 1.04 to 7.73) were the risk of bleeding, while continuation of thienopyridine (OR, 0.23; 95% CI, 0.05 to 1.09) and antiplatelets (OR, 1.83; 95% CI, 0.68 to 4.94) did not increase the risk of bleeding. Conclusions: Continuing thienopyridine and aspirin did not increase the risk of post-ESD. Multiple antiplatelet therapy and a large specimen size were independent risk factors of post-ESD bleeding.
참고문헌 (30)
- Oda I, "Complications of gastric endoscopic submucosal dissection", Dig Endosc, 25(Suppl 1), pp.71~78 (2013)
- Toyonaga T, "1,635 Endoscopic submucosal dissection cases in the esophagus, stomach, and colorectum: complication rates and long-term outcomes", Surg Endosc, 27, pp.1000~1008 (2013)[DOI]
- Lim JH, "Do antiplatelets increase the risk of bleeding after endoscopic submucosal dissection of gastric neoplasms?", Gastrointest Endosc, 75, pp.719~727 (2012)[DOI]
- Cho SJ, "Aspirin use and bleeding risk after endoscopic submucosal dissection in patients with gastric neoplasms", Endoscopy, 44, pp.114~121 (2012)[DOI]
- Koh R, "Antithrombotic drugs are risk factors for delayed postoperative bleeding after endoscopic submucosal dissection for gastric neoplasms", Gastrointest Endosc, 78, pp.476~483 (2013)[DOI]
- Zuckerman MJ, "ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures", Gastrointest Endosc, 61, pp.189~194 (2005)[DOI]
- Eisenberg MJ, "Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents", Circulation, 119, pp.1634~1642 (2009)[DOI]
- ASGE Standards of Practice Committee, "The management of antithrombotic agents for patients undergoing GI endoscopy", Gastrointest Endosc, 83, pp.3~16 (2016)[DOI]
- Veitch AM, "Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines", Endoscopy, 48, pp.385~402 (2016)[DOI]
- Fujimoto K, "Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment", Dig Endosc, 26, pp.1~14 (2014)
- ASGE Standards of Practice Committee, "Management of antithrombotic agents for endoscopic procedures", Gastrointest Endosc, 70, pp.1060~1070 (2009)[DOI]
- Boustiere C, "Endoscopy and antiplatelet agents: European Society of Gastrointestinal Endoscopy (ESGE) guideline", Endoscopy, 43, pp.445~461 (2011)[DOI]
- Igarashi K, "Should antithrombotic therapy be stopped in patients undergoing gastric endoscopic submucosal dissection?", Surg Endosc, 31, pp.1746~1753 (2017)[DOI]
- Furuhata T, "Postoperative bleeding after gastric endoscopic submucosal dissection in patients receiving antithrombotic therapy", Gastric Cancer, 20, pp.207~214 (2017)[DOI]
- Ono S, "Thienopyridine derivatives as risk factors for bleeding following high risk endoscopic treatments: Safe Treatment on Antiplatelets (STRAP) study", Endoscopy, 47, pp.632~637 (2015)[DOI]
- Ono S, "Is it possible to perform gastric endoscopic submucosal dissection without discontinuation of a single antiplatelet of thienopyridine derivatives?", Endosc Int Open, 5, pp.E943~E949 (2017)[DOI]
- Kang HY, "Clinical outcomes of endoscopic submucosal dissection for undifferentiated early gastric cancer", Surg Endosc, 24, pp.509~516 (2010)[DOI]
- Japanese Gastric Cancer Association, "Japanese classification of gastric carcinoma: 3rd English edition", Gastric Cancer, 14, pp.101~112 (2011)[DOI]
- Dong J, "Effects of antithrombotic therapy on bleeding after endoscopic submucosal dissection", Gastrointest Endosc, 86, pp.807~816 (2017)[DOI]
- Hallas J, "Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study", BMJ, 333, pp.726~ (2006)[DOI]
- Douketis JD, "Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines", Chest, 141(2 Suppl), pp.e326S~e350S (2012)[DOI]
- Tounou S, "Continuous aspirin use does not increase post-endoscopic dissection bleeding risk for gastric neoplasms in patients on antiplatelet therapy", Endosc Int Open, 3, pp.E31~E38 (2015)
- Abraham NS, "Risk of lower and upper gastrointestinal bleeding, transfusions, and hospitalizations with complex antithrombotic therapy in elderly patients", Circulation, 128, pp.1869~1877 (2013)[DOI]
- Holster IL, "New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis", Gastroenterology, 145, pp.105~112 (2013)[DOI]
- Ono S, "Delayed bleeding and hemorrhage of mucosal defects after gastric endoscopic submucosal dissection on second-look endoscopy", Gastric Cancer, 19, pp.561~567 (2016)[DOI]
- Okada K, "Risk factors for delayed bleeding after endoscopic submucosal dissection for gastric neoplasm", Surg Endosc, 25, pp.98~107 (2011)[DOI]
- Yoshio T, "Gastric ESD under heparin replacement at high-risk patients of thromboembolism is technically feasible but has a high risk of delayed bleeding: Osaka University ESD study group", Gastroenterol Res Pract, 2013, pp.365830~ (2013)
- Numata N, "Clinical outcomes of endoscopic submucosal dissection for early gastric cancer in patients with chronic kidney disease", J Gastroenterol Hepatol, 28, pp.1632~1637 (2013)
- Fang X, "Continued antiplatelet therapy and risk of bleeding in gastrointestinal procedures: a systematic review", J Am Coll Surg, 222, pp.890~905 (2016)[DOI]
- Shindo Y, "Risk factors for postoperative bleeding after gastric endoscopic submucosal dissection in patients under antithrombotics", World J Gastrointest Endosc, 8, pp.349~356 (2016)[DOI]